• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24014 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for HER2-low unresectable and or metastatic breast cancer after at least one prior line of chemotherapy
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Tunstall TSP – a system for receiving and processing personal alarm alerts
2024     WorkSafeBC COVID-19 and perimyocarditis
2024     Agency for Care Effectiveness (ACE) Selexipag for treating pulmonary arterial hypertension
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Liquid biopsy in the diagnosis of ovarian cancer – a compilation of scientific literature]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding a genetic variant of mucolipidosis type II to the carrier testing offer for people from the Saguenay-Lac-Saint-Jean, Charlevoix, and Haute-Côte-Nord regions]
2024     WorkSafeBC Effectiveness of prolotherapy in rotator cuff tendinopathy
2024     Agency for Care Effectiveness (ACE) Cabotegravir with rilpivirine for treating human immunodeficiency virus type 1 (HIV-1) infection
2024     NIHR Health Technology Assessment programme Infliximab versus alpha interferon in the treatment of Behçet’s disease: the BIO BEHÇET’S RCT
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Indicated prevention of suicide in children and adolescents]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Patiromer (hyperkalaemia in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency echographic multi-spectrometry for bone mineral density assessment]
2024     WorkSafeBC Efficacy/effectiveness of axillary nerve block to treat shoulder pain
2024     Agency for Care Effectiveness (ACE) Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bedaquiline (reassessment after the deadline: pulmonary multidrug-resistant tuberculosis)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fezolinetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of impulse oscillometry (IOS) compared to spirometry]
2024     WorkSafeBC Efficacy/effectiveness of nSTRIDE injection in treating patients with knee osteoarthritis
2024     Agency for Care Effectiveness (ACE) Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia
2024     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post covid and other post infectious diseases]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quizartinib (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     WorkSafeBC Association between complex regional pain syndrome, ketamine use, lower urinary tract symptoms and erectile dysfunction
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: non-physician prescribers' scope of practice]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2024     WorkSafeBC Noise-cancelling headphones as treatment for PTSD - 2024 update
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: development and evaluation of a software tool based on GPT-4 to help sort documents for literature reviews - a proof of concept]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer) – Addendum to Project A23-104]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding two genetic variants of Zellweger spectrum disorder to the carrier testing offer for people from the Saguenay-Lac-Saint-Jean, Charlevoix, and Haute-Côte-Nord regions]
2024     WorkSafeBC Causal association between sprain/strain and myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brolucizumab (neovascular age-related macular degeneration) – Addendum to Project A23-101]
2024     WorkSafeBC Rest as treatment for adhesive capsulitis: 2024 update
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets]
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glofitamab (diffuse large B-cell lymphoma, after ≥ 2 prior therapies)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus) – Addendum to Project A23-112]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative Radiation Therapy for Breast Cancer]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Mental health screening of adults in primary care
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A23-107]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of robotic-assisted orthopedic surgery for knee and hip arthroplasty]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Oncological breast cancer care in selected European countries: cross-sectoral cancer care models
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ivosidenib (acute myeloid leukaemia with IDH1 R132 mutation, first-line, combination with azacitidine)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Artificial Intelligence in health care with a focus on hospitals: methodological considerations for health technology assessment: a scoping review
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) - Addendum to Project A23-122]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pharmacokinetics, efficacy and safety of and persistence with treatment with the generic versions of Concerta compared to Concerta]
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, homozygous) – Addendum to Project A23-123]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge : optimal modalities for organizing and delivering care and services related to radical cystectomy in Quebec]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Strategies for reducing weight stigmatisation towards people with overweight or obesity in the healthcare system]
2024     Agency for Care Effectiveness (ACE) Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer
2024     NIHR Health Technology Assessment programme Linkage of routinely collected NHS data to evaluate liaison mental health services: challenges and lessons learned
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: the experience of people living with neurocognitive disorders in Quebec]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegzilarginase (hyperargininaemia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet in drug-resistant epilepsy]
2024     NIHR Health Technology Assessment programme Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: mitigation strategies to counter the shortage of sublingual nitroglycerin sprays and tablets]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vamorolone (Duchenne muscular dystrophy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Use of telepathology for intraoperative frozen section examination]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Threshold values in health economic evaluations and decision-making
2024     Agency for Care Effectiveness (ACE) Axicabtagene ciloleucel for second-line relapsed or refractory large B-cell lymphoma
2024     Health Technology Wales (HTW) Digital tools for the monitoring and management of wounds
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rezafungin (invasive candidiasis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in dystonia, dyspareunia, and strabismus]
2024     Agency for Care Effectiveness (ACE) Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
2024     NIHR Health Technology Assessment programme Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
2024     Ontario Health Minimally invasive bleb surgery for glaucoma: a health technology assessment
2024     Health Technology Wales (HTW) Low energy contact x-ray brachytherapy (CXB) for the treatment of early stage rectal cancer
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Momelotinib (myelofibrosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [CAR-based immunotherapy with a focus on CAR-NK cells]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Telehealth in diabetes – EU mapping and systematic evaluation of organisational aspects
2024     Ontario Health Intrathecal drug delivery systems for cancer pain
2024     Health Technology Wales (HTW) Video feedback interventions to improve communication within family relationships and support children at risk
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of regular searches in the ICTRP Search Portal]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Skin cancer prevention: Guideline recommendations for primary and secondary prevention]
2024     Ontario Health Level 2 polysomnography for the diagnosis of sleep disorders: a health technology assessment
2024     Health Technology Wales (HTW) Intensive family preservation programmes for families in crisis
2024     NIHR Health Technology Assessment programme Evidence of quality of life for hospitalised patients with COVID-19: a scoping review
2024     Austrian Institute for Health Technology Assessment (AIHTA) Point of care tests (POCT): D-dimer and troponin (Update 2024)
2024     Ontario Health Sucrose octosulfate (SOS)-impregnated dressings for adults with difficult-to-heal noninfected diabetic foot ulcers and difficult-to-heal noninfected venous leg ulcers
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: KIT D816V mutation detection by NAAT]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Caval valve implantation (CAVI) for severe tricuspid regurgitation
2024     NIHR Health Services and Delivery Research programme Routine outcomes to investigate differences between ethnic minorities and white British people presenting to emergency services for injury: the stakeholder consultation
2024     Ontario Health Fractional exhaled nitric oxide testing for the diagnosis and management of asthma: a health technology assessment
2024     Scottish Health Technologies Group (SHTG) Lung cancer AI
2024     The Danish Health Technology Council (DHTC) [Guided, internet-based cognitive behavioral therapy for the treatment of adults with mild or moderate depression]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia
2024     Ontario Health Pelvic floor muscle training for stress urinary incontinence, fecal incontinence, and pelvic organ prolapse: a health technology assessment
2024     Scottish Health Technologies Group (SHTG) Colon capsule endoscopy
2024     Austrian Institute for Health Technology Assessment (AIHTA) Thermoablation for benign thyroid nodules
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: overview of thrombectomy for the treatment of ischemic stroke in Québec – Portrait from 2017-2018 to 2019-2020]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD). 3rd Update
2024     Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non–small cell lung cancer: a health technology assessment
2024     Health Information and Quality Authority (HIQA) Health technology assessment of Herpes Zoster (shingles) vaccination
2024     Gesundheit Osterreich GmbH (GOeG) [Fecal immunochemical tests in comparison: umbrella review]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Renal denervation (RDN) in patients with treatment resistant hypertension. 2nd Update
2024     Canary Health Service [Safety and efficacy of the use of compression garments in the treatment of lipedema]
2024     Health Information and Quality Authority (HIQA) Enhanced inactivated influenza vaccines for over 65s: protocol for a health technology assessment